To determine whether tumour EVs upregulate tenascin-C in primary fibroblasts via the NF-κB pathway, we included an NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ) [39], in combination with J82 EV treatment. Here, NFKB1 is linked to neoplasm.